Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas. Show more

6801 N. Capital of Texas Highway, Austin, TX, 78731, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

104.3M

52 Wk Range

$1.15 - $4.98

Previous Close

$2.16

Open

$2.17

Volume

2,248,995

Day Range

$2.14 - $2.49

Enterprise Value

44.56M

Cash

106.1M

Avg Qtr Burn

-6.221M

Insider Ownership

12.92%

Institutional Own.

28.96%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Simufilam Details Tuberous Sclerosis Complex (TSC)-related epilepsy	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Simufilam (PTI-125) Details Alzheimer's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.